Pitavastatin for lowering lipids
Referencias
Additional references
Adams SP, Sekhon SS, Wright JM. Rosuvastatin for lowering lipids. Cochrane Database of Systematic Reviews 2014, Issue 11. [DOI: 10.1002/14651858.CD010254.pub2]
Adams SP, Tsang M, Wright JM. Atorvastatin for lowering lipids. Cochrane Database of Systematic Reviews 2015, Issue 3. [DOI: 10.1002/14651858.CD008226.pub3]
Adams Stephen P, Sekhon Sarpreet S, Wright James M, Tsang Michael. Fluvastatin for lowering lipids. Cochrane Database of Systematic Reviews 2016, Issue 7. [DOI: 10.1002/14651858.CD012282]
Adams SP, Tiellet N, Wright JM. Cerivastatin for lowering lipids. Cochrane Database of Systematic Reviews 2017, Issue 1. [DOI: 10.1002/14651858.CD012501]
Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosaJC, Nestel PJ, et al. Association of LDL cholesterol, non‐HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta‐analysis. JAMA 2012;307(12):1302–9.
Centers for Disease Control and Prevention (CDC). Million hearts: strategies to reduce the prevalence of leading cardiovascular disease risk factors‐‐United States, 2011. MMWR ‐ Morbidity & Mortality Weekly Report 2011;60(36):1248‐51. [MEDLINE: 21918495]
Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Cholesterol Treatment Trialists (CTT) Collaborators. Efficacy and safety of cholesterol‐lowering treatment: prospective meta‐analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366(9493):1267‐78. [MEDLINE: 16214597]
Edwards JE, Moore RA. Statins in hypercholesterolaemia: a dose‐specific meta‐analysis of lipid changes in randomised, double blind trials. BMC Family Practice 2003;4:18. [MEDLINE: 14969594]
Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(1):7‐10. [MEDLINE: 16360555]
Gaw A, Packard CJ, Shepherd J. Statins : the HMG CoA Reductase Inhibitors in Perspective. London, England: Martin Dunitz Ltd, 2000. [1853174688]
Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Journal of the American College of Cardiology 2004;44(3):720–32. [MEDLINE: 15358046]
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine 2002;21(11):1539‐58. [MEDLINE: 12111919]
Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Kellick KA, Burns K, McAndrew E, Haberl E, Hook N, Ellis AK. Focus on atorvastatin: An HMG‐CoA reductase inhibitor for lowering both elevated LDL cholesterol and triglycerides in hypercholesterolemic patients. Formulary 1997;32(4):352‐63. [EMBASE: 1997129035]
Kreatsoulas C, Anand SS. The impact of social determinants on cardiovascular disease. Canadian Journal of Cardiology 2010;26(Suppl C):8C–13C. [MEDLINE: 20847985]
Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta‐analysis. BMJ 2003;326(7404):1423. [MEDLINE: 12829554]
Liao JK, Laufs U. Pleiotropic effects of statins. Annual Review of Pharmacology and Toxicology 2005;45:89‐118.
Moghadasian MH. Clinical pharmacology of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors. Life Sciences 1999;65(13):1329–37. [MEDLINE: 10503952]
Mukhtar RYA, Reid J, Reckless JPD. Pitavastatin. International Journal of Clinical Practice 2005;59(2):239‐52. [MEDLINE: 15854203]
The Nordice Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordice Cochrane Centre, The Cochrane Collaboration, 2014.
Roger VL, Go AS, Lloyd‐Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics‐‐2011 update: a report from the American Heart Association. Circulation 2011;123(4):e18–e209. [MEDLINE: 21160056]
Schaefer EJ, McNamara JR, Tayler T, Daly JA, Gleason JL, Seman LJ, et al. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects. American Journal of Cardiology 2004;93(1):31‐9. [MEDLINE: 14697462]
Schectman G, Hiatt J. Dose‐response characteristics of cholesterol‐lowering drug therapies: Implications for treatment. Annals of Internal Medicine 1996;125(12):990‐1000. [MEDLINE: .8967711]
Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH (editors). Chapter 11: Presenting results and ’Summary of findings’ tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. available from www.cochrane‐handbook.org.
Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al (editors). Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. available from www.cochrane‐handbook.org.
Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. available from www.cochrane‐handbook.org.
Teramoto T, Shimano H, Yokote K, Urashima M. Effects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL‐C) in hypercholesterolemia. Journal of Atherosclerosis and Thrombosis 2009;16(5):654‐61. [MEDLINE: 19907105]
Tsang MB, Adams SP, Jauca C, Wright JM. In some systematic reviews placebos may not be necessary: an example from a statin dose‐response study. 10th Cochrane Colloquium. Stavanger, 31 July ‐ 3 August 2002; Vol. Abstracts:Poster 29.
Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technology Assessment (Winchester, England) 2007;11(14):1‐160, iii‐iv. [MEDLINE: 17408535]
